|
|
|
Volumn 63 Suppl 2, Issue , 2005, Pages 483-487
|
|
NAVIGATOR trial (nateglinide)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIDIABETIC AGENT;
CYCLOHEXANE DERIVATIVE;
DRUG DERIVATIVE;
INSULIN;
NATEGLINIDE;
PHENYLALANINE;
BIOASSAY;
CARDIOVASCULAR DISEASE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
GLUCOSE INTOLERANCE;
HUMAN;
INSULIN RESISTANCE;
LIFESTYLE;
NON INSULIN DEPENDENT DIABETES MELLITUS;
PATHOPHYSIOLOGY;
PRIMARY PREVENTION;
RANDOMIZED CONTROLLED TRIAL;
REVIEW;
RISK;
SECRETION;
CARDIOVASCULAR DISEASES;
CYCLOHEXANES;
DIABETES MELLITUS, TYPE 2;
ENDPOINT DETERMINATION;
GLUCOSE INTOLERANCE;
HUMANS;
HYPOGLYCEMIC AGENTS;
INSULIN;
INSULIN RESISTANCE;
LIFE STYLE;
PHENYLALANINE;
PRIMARY PREVENTION;
RANDOMIZED CONTROLLED TRIALS;
RISK;
|
|
EID: 20144379339
PISSN: 00471852
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (2)
|
|
References (11)
|
